CN109715826A - 用于评估癌症的多重优化错配扩增（moma）实时pcr - Google Patents

用于评估癌症的多重优化错配扩增（moma）实时pcr Download PDF

Info

Publication number
CN109715826A
CN109715826A CN201780039835.XA CN201780039835A CN109715826A CN 109715826 A CN109715826 A CN 109715826A CN 201780039835 A CN201780039835 A CN 201780039835A CN 109715826 A CN109715826 A CN 109715826A
Authority
CN
China
Prior art keywords
cancer
method described
snv target
snv
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780039835.XA
Other languages
English (en)
Chinese (zh)
Inventor
青·富田·米切尔
卡尔·斯塔姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical College of Wisconsin
Original Assignee
Medical College of Wisconsin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical College of Wisconsin filed Critical Medical College of Wisconsin
Publication of CN109715826A publication Critical patent/CN109715826A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201780039835.XA 2016-04-29 2017-04-29 用于评估癌症的多重优化错配扩增（moma）实时pcr Pending CN109715826A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662330043P 2016-04-29 2016-04-29
US62/330,043 2016-04-29
PCT/US2017/030291 WO2017190104A1 (en) 2016-04-29 2017-04-29 Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer

Publications (1)

Publication Number Publication Date
CN109715826A true CN109715826A (zh) 2019-05-03

Family

ID=58709564

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780039835.XA Pending CN109715826A (zh) 2016-04-29 2017-04-29 用于评估癌症的多重优化错配扩增（moma）实时pcr

Country Status (11)

Country Link
US (1) US20200181681A1 (enExample)
EP (1) EP3449014A1 (enExample)
JP (2) JP2019518437A (enExample)
CN (1) CN109715826A (enExample)
AU (1) AU2017258799A1 (enExample)
BR (1) BR112018072195A2 (enExample)
CA (1) CA3022545A1 (enExample)
EA (1) EA201892491A1 (enExample)
IL (1) IL262640A (enExample)
MX (1) MX2018013223A (enExample)
WO (1) WO2017190104A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110177874A (zh) * 2016-11-02 2019-08-27 威斯康星州立大学医学院 用于使用错配扩增和统计方法来评估风险的方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
JP6153874B2 (ja) 2011-02-09 2017-06-28 ナテラ， インコーポレイテッド 非侵襲的出生前倍数性呼び出しのための方法
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
DK3294906T3 (en) 2015-05-11 2024-08-05 Natera Inc Methods for determining ploidy
CN109477138A (zh) 2016-04-15 2019-03-15 纳特拉公司 肺癌检测方法
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
EP3642353B1 (en) 2017-06-20 2025-03-05 The Medical College of Wisconsin, Inc. Assessing transplant complication risk with total cell-free dna
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
CN112236535A (zh) 2018-04-14 2021-01-15 纳特拉公司 用于借助于循环肿瘤dna的个人化检测的癌症检测和监测的方法
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011118603A1 (ja) * 2010-03-24 2011-09-29 凸版印刷株式会社 競合プライマーによる標的塩基配列の検出方法
CA2875281A1 (en) * 2012-05-29 2013-12-05 Abbott Molecular, Inc. Methods of detecting single nucleotide polymorphisms at codon 600 of human braf

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
CA2282504A1 (en) 1997-02-25 1998-08-27 Jun-Ping Xu Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US20030148301A1 (en) * 1999-12-10 2003-08-07 Toshiya Aono Method of detecting nucleotide polymorphism
JP4116856B2 (ja) * 2002-10-02 2008-07-09 富士フイルム株式会社 １塩基多型の検出方法
US20140242582A1 (en) 2013-02-28 2014-08-28 Ariosa Diagnostics, Inc. Detection of genetic abnormalities using ligation-based detection and digital pcr
DK3194612T3 (da) * 2014-08-22 2024-10-14 Resolution Bioscience Inc Fremgangsmåder til kvantitativ genetisk analyse af cellefrit dna
CA2984352A1 (en) * 2015-04-30 2016-11-03 Aoy Tomita Mitchell Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cell-free dna

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011118603A1 (ja) * 2010-03-24 2011-09-29 凸版印刷株式会社 競合プライマーによる標的塩基配列の検出方法
CA2875281A1 (en) * 2012-05-29 2013-12-05 Abbott Molecular, Inc. Methods of detecting single nucleotide polymorphisms at codon 600 of human braf

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALOIS H. LANG 等: "Optimized Allele-Specific Real-Time PCR Assays for the Detection of Common Mutations in KRAS and BRAF", 《JMD JANUARY》 *
BENOIT LEFEBURE 等: "Prognostic Value of Circulating Mutant DNA in Unresectable Metastatic Colorectal Cancer", 《ANNALS OF SURGERY》 *
OLIVER STROHMEIER 等: "Multiplex genotyping of KRAS point mutations in tumor cell DNA by allele-specific real-time PCR on a centrifugal microfluidic disk segment", 《MICROCHIM ACTA》 *
RUTH E. BOARD 等: "Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer", 《BREAST CANCER RES TREAT》 *
WARREN E. GLAAB 等: "A novel assay for allelic discrimination that combines the fluorogenic 5X nuclease polymerase chain reaction (TaqMan)and mismatch amplification mutation assay", 《MUTATION RESEARCH》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110177874A (zh) * 2016-11-02 2019-08-27 威斯康星州立大学医学院 用于使用错配扩增和统计方法来评估风险的方法

Also Published As

Publication number Publication date
JP2019518437A (ja) 2019-07-04
IL262640A (en) 2018-12-31
MX2018013223A (es) 2019-04-22
AU2017258799A1 (en) 2018-12-20
EA201892491A1 (ru) 2019-06-28
US20200181681A1 (en) 2020-06-11
EP3449014A1 (en) 2019-03-06
CA3022545A1 (en) 2017-11-02
WO2017190104A1 (en) 2017-11-02
BR112018072195A2 (pt) 2019-02-12
JP2022084647A (ja) 2022-06-07

Similar Documents

Publication Publication Date Title
CN109715826A (zh) 用于评估癌症的多重优化错配扩增（moma）实时pcr
JP7713054B2 (ja) 循環細胞の分析方法
US20250003000A1 (en) Methods for detection of donor-derived cell-free dna
JP7030860B2 (ja) 変異の検出および染色体分節の倍数性
JP7145907B2 (ja) 疾患細胞不均一性を示す疾患の検出および処置、ならびに通信試験結果のためのシステムおよび方法
Fischer et al. Intraductal papillary mucinous neoplasms arise from multiple independent clones, each with distinct mutations
US20230287497A1 (en) Methods for detection of donor-derived cell-free dna
US20210257048A1 (en) Methods and systems for calling mutations
JP2024103502A (ja) ニューラルネットワークを使用して倍数性状態を呼び出すための方法およびシステム
JP2021520816A (ja) 循環腫瘍ｄｎａの個別化された検出を用いる癌検出およびモニタリングの方法
CN119032182A (zh) 用于癌症检测和监测的方法
AU2019233897B2 (en) Tissue-specific methylation marker
US20200392584A1 (en) Methods and systems for detecting residual disease
CN109477138A (zh) 肺癌检测方法
CN108138209A (zh) 通过原位扩增制备细胞游离核酸分子的方法
JP2022550596A (ja) シングルセルで同時に検出されるコピー数変動及び単一ヌクレオチド変動のための方法、システム、及び装置
KR20240049800A (ko) 비정상적으로 메틸화된 단편을 갖는 체세포 변이 동시 발생
Atli et al. Pros and cons for fluorescent in situ hybridization, karyotyping and next generation sequencing for diagnosis and follow-up of multiple myeloma
Gleeson et al. Molecular cytology genotyping of primary and metastatic GI stromal tumors by using a custom two-gene targeted next-generation sequencing panel with therapeutic intent
Amoako et al. Targeted gene panel sequencing of liquid and tissue biopsies reveals actionable genomic alterations in Ghanaian metastatic breast cancer cases
Xia et al. Baseline mutation profiling of 1134 samples of circulating cell-free DNA and blood cells from healthy individuals
Prieto-Remon et al. Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
HK40063633A (en) Methods for analysis of circulating cells
HK40063633B (en) Methods for analysis of circulating cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190503

WD01 Invention patent application deemed withdrawn after publication